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ABSTRACT 30 
The tumor microenvironment and its contribution to tumorigenesis has been a focal highlight in 31 
recent years. A two-way communication between the tumor and the surrounding 32 
microenvironment sustains and contributes to the growth and metastasis of tumors. 33 
Progression and metastasis of hepatocellular carcinoma have been reported to be exceedingly 34 
influenced by diverse microenvironmental cues. In this study, we present a 3D-culture model of 35 
liver cancer to better mimic in vivo tumor settings. By creating novel 3D co-culture model that 36 
combines free-floating and scaffold based 3D-culture techniques of liver cancer cells and 37 
fibroblasts, we aimed to establish a simple albeit reproducible ex vivo cancer microenvironment 38 
model that captures tumor-stroma interactions. The model presented herein exhibited unique 39 
gene expression and protein expression profiles when compared to 2D and 3D mono-cultures 40 
of liver cancer cells. Our results showed that in vivo like conditions cannot be mimicked by 41 
simply growing cancer cells as spheroids, but by co-culturing them with 3D fibroblast with 42 
which they were able to cross-talk. This was evident by the upregulation of several pathways 43 
involved in HCC, and the increase in secreted factors by co-cultured cancer cells, many of which 44 
are also involved in tumor-stroma interactions. Compared to the conventional 2D culture, the 45 
proposed model exhibits an increase in the expression of genes associated with development, 46 
progression, and poor prognosis of HCC. Our results correlated with an aggressive outcome that 47 
better mirrors in vivo HCC, and therefore, a more reliable platform for molecular understanding 48 
of HCC and possibly better anti-cancer drug screening.  49 
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INTRODUCTION 50 
        Cancer is a multi-factorial disease, arising from normal cells, primarily through abnormal 51 
cellular proliferation and progressive mutation load. Tumor cells, however, represent only one 52 
aspect of tumorigenesis. The tumor milieu is composed of a dynamic network of non-malignant 53 
cellular components, non-cellular components, signaling molecules, and extracellular matrix 54 
(ECM) [1,2], which collectively forms the tumor microenvironment (TME). A dynamic two-way 55 
communication between the tumor and the surrounding milieu, sustains and contributes to 56 
tumor growth and metastasis [3]; thereby highlighting the key role the TME plays in tumor 57 
progression  [1,4]. In addition, many studies have reported the positive role of the TME in 58 
restraining tumor initiation and progression at initial stages of carcinogenesis [5], and how “re-59 
programming” the TME in the later stages holds a great potential for developing effective 60 
cancer treatments [1].  61 
Fibroblasts are generally considered the predominant cellular TME component. Whilst 62 
normally in an “inactive” quiescent state; fibroblasts recruited to the tumor site are constantly 63 
activated by the tumor through paracrine signaling, after which they are transformed into 64 
cancer-associated fibroblasts (CAFs) [6]. Once the CAF transition is triggered, paracrine signaling 65 
is no longer needed [7]. These transformed CAFs become distinct in their morphology and 66 
function from normal fibroblasts [7], most likely due to their rewiring by tumor signaling. CAFs 67 
possess higher ability to proliferate [8], be tumor proximal, and evade apoptosis [9]. But the 68 
molecular mechanisms mediating this process remains elusive. CAFs contribute significantly to 69 
tumorigenesis; partly through suppressing immune responses, secreting growth factors, 70 
cytokines, and proangiogenic factors [10]. In addition, CAFs contribute to tumorigenesis 71 
through secreting ECM proteins and degrading matrix metalloproteinase (MMPs), which 72 
together, give CAFs their ECM remodeling ability [10]. CAFs, therefore, have potential as 73 
therapeutic targets [11]. 74 
A tumor has an increasing demand for oxygen and nutrients to support its progression. 75 
When the demand for oxygen remains unmet, low oxygen hypoxic  conditions ensue [12]. To 76 
survive, tumor cells activate the hypoxia-inducible factor 1 (HIF1) [12], which in turn activates 77 
the transcription of a group of genes through binding to their hypoxia-response elements to 78 
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promote the survival of tumor cells [13]. HIF-1 targeted genes significantly contribute to tumor 79 
angiogenesis, metastasis, adhesion, metabolism, and pH regulation [13]. Moreover, many 80 
studies have highlighted the role of hypoxia in recruiting stromal components to the TME [14], 81 
ECM composition, and metastatic remodeling [15]  82 
Hepatocellular carcinoma (HCC), is the fifth most common cancer and is the fourth cause 83 
of cancer-related death worldwide [16]. HCC has a very poor prognosis with only five-year 84 
survival rate [17]. HCC progression is influenced by the liver microenvironment such as altered 85 
stromal cells [18]. These cells deposit ECM proteins causing fibrosis that then progresses to 86 
cirrhosis with a prevalence of 80-90% [18]; suggesting a crucial role of ECM build-up in HCC 87 
progression [19]. Hypoxia represents a driving force for HCC progression, and is associated with 88 
poor prognosis [20]. HIF-mediated gene expression contributes to different aspects of HCC 89 
metastasis, such as epithelial mesenchymal transition (EMT) [21], invasion of the ECM, and 90 
metastasis [22]. Yet the molecular mechanisms governing stromal and tumor cell interactions 91 
within the TME of HCC under hypoxic conditions [14] remains unclear. 92 
To reflect the complexity and dynamic nature of tumor cell biology, a physiologically 93 
relevant model is needed. Especially, when it comes to drug discovery and identifying effective 94 
therapeutic targets. To simulate in vivo environment, in vitro two-dimensional (2D) cell culture 95 
is typically assembled by growing cells commonly on a plastic substrate in an adherent 96 
monolayer. However, distortion of spatial arrangement of cells in 2D culture changes cell-cell 97 
and cell-matrix interactions [23], and most importantly, alters the response of cells to certain 98 
drugs and treatments [24]. That is why, 3D cultured cells better recapitulates in vivo 99 
architecture of tumors and exhibits gene expression closer to that of in vivo tumors [23]. One 100 
very common 3D cultured cells model is the spheroid; a micro cell cluster sphere [25]. The 101 
nature of this three-dimensional multicellular model is what makes it an attractive tool to 102 
simulate solid tumors in vitro as it is composed of three regions, a highly proliferative outer 103 
region, a middle quiescent region, and a hypoxic core region [26]. Such compartmentalization 104 
creates diffusional gradients of oxygen, nutrients, and tested drugs among all three regions of 105 
the spheroid, which is also characteristic of solid tumors [27]. 106 
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We aimed at modeling the basic TME of liver cancer by mimicking certain aspects of in vivo 107 
tumors, such as three-dimensionality of tissue, hypoxia, and heterogeneity of tumors. Five 108 
groups were designed to reflect each element, group 1 is a control group for comparison 109 
purposes which consists of 2D mono-cultures of liver cancer cells. Group 2 is also 2D mono-110 
cultures of liver cancer cells but induced for hypoxia chemically. Group 3 on the other hand is 111 
like group 2 but additionally includes conditioned media from 2D fibroblasts to reflect a one-112 
way co-culture system. Group 4 and 5 are 3D cultures of liver cancer cells that exhibit hypoxia 113 
physiologically due to culturing conditions. However, group 5, which is our proposed model, 114 
includes a 3D culture of fibroblast in a separate insert, reflecting a two-way co-culture system. 115 
Our findings reported herein demonstrate that our proposed model of group 5 reflects many 116 
aspects of in vivo settings and signaling pathways, promoting it as a potential platform for 117 
further studies of drug efficacy in vitro and understanding the communication between cancer 118 
and the stroma in liver cancer. 119 
 120 
MATERIALS AND METHODS 121 
Co-culture Systems 122 
For the 2D co-culture, a one-way communication system was followed. Briefly, HepG2 and SV-123 
80 cells were seeded at a density of 1X 10
6
 in conventional 2D culturing flasks in DMEM media. 124 
Flasks were incubated at 37°C in 5% CO2 humidified incubator for about 24 hours. Conditioned 125 
media of SV-80 cell line was collected, centrifuged to collect any cellular debris, and applied to 126 
HepG2 cells, which were incubated with the conditioned media for 48 hours. 127 
For the 3D co-culture, a two-way communication system was followed. Briefly, HepG2 and SV-128 
80 3D cultures were prepared separately. Prior to co-culture, 6-well plates were coated with 129 
1.5% agarose, and allowed to set and cool before transferring HepG2 spheres to the bottom of 130 
the coated plates, and the inserts containing SV-80 3D culture were placed on top. HepG2 and 131 
SV-80 3D cultures were incubated for 48 hours. 132 
The remaining materials and methods are included in supplementary data. 133 
 134 
 135 
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RESULTS 136 
Comparing 2D, mono- 3D, and co- 3D cultures and their gene expression   137 
Fibroblasts grown as a 2D culture exhibit an elongated morphology. However, growing 138 
fibroblasts as 3D culture in porous scaffolds alters their morphology to be more rounded. 139 
HepG2 cells grown in 3D were monitored over a period of 5 days to assess formation of tight 140 
spheroids with a smooth surface (Fig. 1A-B. HepG2 2D cultures were treated with increasing 141 
concentrations of CoCl2 (100-400 μM) to assess cellular viability under hypoxia-mimicking 142 
conditions (Fig. 1C). Treatment of HepG2 with CoCl2 did not affect cellular viability significantly 143 
at doses of 100 and 200 μM of CoCl2. However, a highly significant difference (p < 0.001) was 144 
noted at a dose of 400 μM CoCl2. To confirm the induction of hypoxia in CoCl2- treated HepG2 145 
2D cultures, protein expression of HIF1α was assessed using western blot. Treatment with 200 146 
μM of CoCl2 for 6 hours did not induce HIF1α expression. However, by increasing the dose to 147 
300 μM, HIF1α expression was detected in HepG2 cells (Fig. 1D). Immunofluorescence was then 148 
used to detect the cellular localization of HIF1α, showing that CoCl2 also affects HIF1α 149 
translocation to the nucleus (Fig. 1E), where it can bind to hypoxia-response elements (HREs). 150 
 151 
Differential gene expression analysis 152 
To better assess in vivo mimicking capabilities of our 5 groups, RNA from the denoted samples 153 
(Fig. 1A) were extracted and then sequenced via the Illumina platform. Significant differentially 154 
expressed genes (DEGs) were determined at a cutoff of Log2FC of 1 and FDR < 0.05. A 155 
hierarchical clustering Heatmap was used to explore changes in global gene expression across 156 
our 5 models (Fig. 2 A). Interestingly, group 5 clustered separately from the rest, revealing a 157 
fundamental and distinctive change in gene expression. Principal component analysis (PCA) 158 
based on the global gene expression showed a similar outcome, where group 5 segregated at 159 
the opposite extreme of all other groups, with the conventional HepG2 culture (group 1) being 160 
the most distant (Fig. 2B), suggesting fundamental differences between 2D, monocellular 3D, 161 
and multicellular 3D models.  162 
Significant differentially expressed genes (DEG) were determined relative to group 1 using RNA-163 
seq 2G. Group2 resulted in significant upregulation of 243 genes and downregulation of 131 164 
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genes. Group3 increased the number of significantly DEGs to 474 upregulated and 145 165 
downregulated genes. When comparing gene expression profile of group 4 to group 1, 203 166 
genes were significantly upregulated, whereas 82 genes were downregulated. Group 5 167 
dramatically changed the gene expression of HepG2 by significantly upregulating 1291 and 168 
downregulating 880 genes in group 5 in comparison to group 1. PCA plot based on the DEGs 169 
showed similar results to the global expression PCA plot, whereby group 5 was segregating 170 
separately from the remaining groups (Fig. 2C). In Addition, significant DEGs signatures, unique 171 
to each group, were identified (Fig. 2D). Group 5 exhibited the highest number in unique 172 
significant DEGs among all other groups, at 957 upregulated genes and 796 downregulated 173 
genes. A full List of common and unique significantly DEGs of each group is available in 174 
supplementary files 1 and 2. 175 
Canonical pathways associated with significant DEGs in different culturing conditions were 176 
analyzed using gene-based enrichment analysis by XGR. As expected, culturing HepG2 cells 177 
under hypoxia-mimicking conditions (group 2 and 3) upregulated genes involved in hypoxia-178 
inducible factor-1 alpha (HIF1-α) and hypoxia-inducible factor-2 alpha (HIF2-α) pathways, and 179 
networks downstream of these pathways. This was even observed in 3D spheroid cultures 180 
(group 4 and 5) despite not being treated with a hypoxia inducing agent, indicating the 181 
formation of hypoxic core in 3D culture spheroids. Culturing HepG2 cells with only fibroblasts 182 
conditioned media (group 3) or alternatively with 3D culture of fibroblasts (group 5) 183 
upregulated genes involved in integrin family cell surface interactions, interleukin-6 (IL6) 184 
mediated signaling events (Table S1). 185 
 186 
In-depth pathway functional analysis reveals pathways associated with HCC progression. 187 
To further understand the role of significant DEGs in each group, we applied clustering analysis 188 
using ClueGO/CluePedia as described previously [28] . By combining Gene Ontology (GO) terms, 189 
KEGG and Wiki pathways, ClueGo/CluePedia create a better interpretation of the pathways 190 
associated with the list of input genes [29] . Hypoxia mimicking conditions in group 2 induced 191 
cellular responses to hypoxia and HIF-1 signaling pathway, as well as other signaling pathways 192 
reported to promote HCC including NRF2, FOXO, and p53 pathways [30,31] (Fig. 3A-B). 193 
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Similarly, inducing hypoxia in group 3 resulted in inducing HIF-1 signaling pathways. However, 194 
with the addition of fibroblast conditioned media, group 3 DEGs-associated processes were 195 
enriched in 3 out of 5 pathways previously reported in KEGG analysis of HCC patients’ tissues 196 
including i) complement and coagulation cascades, ii) focal adhesion, and iii) ECM-receptor 197 
interaction [32] (Fig. 3A). DEGs-associated processes of HepG2 3D culture alone (group 4) 198 
resembled some of group 2 such as hypoxia and NRF2 signaling pathways, but also some of 199 
group 3 such as G3 such as complement and coagulation cascades (Fig. 3A). Additionally, DEGs-200 
associated processes of group 4 included steroid hormone biosynthesis process and estrogen 201 
signaling pathway, which have been linked to HCC progression [33] (Fig. 3A). Group 5 shared 202 
some pathways with the other groups such as hypoxia, focal adhesion, glycolysis/ 203 
gluconeogenesis, and estrogen signaling pathway. In addition, DEGs-associated processes of 204 
group 5 were significantly enriched in HCC-promoting pathways including oncostatin M 205 
signaling pathway, insulin signaling pathway and aryl hydrocarbon receptor pathways [34,35] 206 
(Fig. 3B).  207 
After identifying the main pathways involved in group 5 through ClueGO/CluePedia clustering, 208 
Insulin signaling pathway was further analyzed and visualized in PathVisio due to its 209 
documented relevance in HCC [36] and to gain insights of significant physiological changes 210 
occurring within a specific pathway. Genes below FDR 0.05 (5871 hits) were imported into 211 
PathVisio [37] to identify trends in regulation within this particular pathway and other chained 212 
events embedded within associated pathways. Inconsistencies within these maps were 213 
excluded from the final pathway (Fig. 4). The Insulin signaling pathway in group 5 was found to 214 
mainly lead to activation of genes involved MAPK signaling and this trend converges with 215 
hypoxia signaling input, both leading to the production of VEGFB, VEGFA, PGF, growth factors 216 
known to be involved in angiogenesis and tumor invasion [38]. Tumor invasion can also be 217 
promoted via Ras and its downstream pathways of MAPK and RALB, which were all shown to be 218 
upregulated in group 5.  Some of the genes involved in the pathway shown previously have 219 
been validated with qPCR (Fig. 5A). 220 
 221 
Co-culture of Fibroblasts and HepG2 3D cultures enriches the secretome in pro-tumor factors 222 
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To identify signaling factors playing a role in the crosstalk between cancer cells and fibroblasts, 223 
the secretome of group 4 and 5 was analyzed for factors involved in angiogenesis, invasion, and 224 
metastasis, in addition to other factors in the insulin signaling pathway, secretome of 3D 225 
fibroblasts was included as a control (Fig S2, Fig. 5B-F). Most factors were dramatically 226 
increased in the secretome of group 5 (from both fibroblasts and HepG2 cells) when compared 227 
to 3D mono-cultures. Co-culturing HepG2 spheroids with 3D culture of fibroblasts increased the 228 
levels of insulin signaling pathway factors like IGF-II, IGFBP1, IGFBP2 (Fig 5B). In addition, levels 229 
of different angiogenesis and cytokines that are involved in the cross-talk in the TME were 230 
highly increased in the setting of group 5 (Fig 5C & F).  231 
As the secretome collected from group 5 is shared among fibroblasts and HepG2 cells, we 232 
wanted to confirm the source of the secreted factors. To that end we compared gene 233 
expression of 3D HepG2 or 3D fibroblasts before and after co-culture (group 5 over group 4) 234 
(Fig. 5G). Differential gene expression analysis revealed that M-CSF, IGFBP1, IGFBP2, TGF-β, and 235 
PECAM-1 were upregulated in HepG2 cells after co-culture, while they were not differentially 236 
expressed in fibroblasts. On the other hand, TGF-α, and IL-1β were only differentially expressed 237 
in fibroblasts after co-culture. VEGF and IGF-II were differentially expressed in both HepG2 cells 238 
and fibroblasts, being more upregulated in HepG2 cells (Fig. 5G). Despite that VEGF is 239 
upregulated more than 2.5 folds on the RNA level in HepG2 cells after co-culture (Fig. 5G), there 240 
was no noticeable difference in the secreted VEGF from 3D HepG2 cells before and after co-241 
culture (Fig. 5F). Nonetheless, VEGFR2 was more expressed in group 5 in comparison to group 1 242 
and group 4; while VEGFR1 was higher in the 3D cultures, but no noticeable difference between 243 
the two (Fig. 5H). TNFR1 was also dramatically higher in group 5 when compared to both group 244 
1 and group 4 (Fig. 5H). Kaplan-Meier curves of genes within our main pathway of interest were 245 
analyzed. IGF1R and EGLN3 showed a significant correlation between expression and prognosis 246 
(Fig. 5 I-J). Both genes were shown to be involved in insulin signaling pathway (Fig. 4). 247 
 248 
Pathway complementation analysis highlights regulatory miRNAs and prognosis markers 249 
To better understand the changes elicited by the 3D co-culture conditions on HepG2 cells, we 250 
investigated the effect of miRNA regulation given their role in affecting de novo or modulating 251 
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established gene expression in tumors [39,40]. Based on miRNA-gene interaction analysis of 252 
significant DEGs in group 5, miR-335 was the top regulatory miRNA with the highest number of 253 
connections to other genes in the network (Fig. S4 A). Other miRNAs were predicted, top 10 are 254 
shown in Fig. S4 B with literature citations (full list is available in Table S2).  255 
DISCUSSION 256 
Establishment of 3D culture models 257 
We investigated the bilateral effect of the cellular architecture and milieu on the properties and 258 
phenotypic responses of the whole cellular microenvironment of tumor cells. Liver cancer 259 
microenvironment was modeled using 2D and 3D mono- and co-culture systems. The 260 
transcriptome of five models was profiled to determine the effects of each condition. Each one 261 
of the culturing conditions mimicked an aspect of the TME. Based on our clustering methods, 262 
group 5 clustered away all the other groups, specifically group 1, in both the PCA plot and 263 
hierarchical cluster heatmap (Fig. 2 A-C). This is in line with the Venn diagram, where group 5 264 
had the highest number of unique genes that are not shared with other groups (Fig. 2D). This 265 
clear distinction suggests a fundamental difference in gene expression between the proposed 266 
model of group 5 and all other culturing conditions, signifying a considerable change in gene 267 
expression as a result of 3D co-culture of cancer spheroids with fibroblasts.  268 
 269 
Mimicking hypoxic conditions is not sufficient to mimic in vivo conditions 270 
Treatment with hypoxia mimicking agent significantly upregulated genes associated with p53 271 
and AP-1 networks (Table S1). AP-1 proteins (i.e. Jun, Fos, and ATF families) are activated by 272 
hypoxia and are frequently deregulated in cancer [41]. Deregulation of ATF-2 and its network 273 
have been implicated in liver development, regeneration, and cirrhosis [42]. In addition, ATF-2 274 
has been reported to play a role in HCC resistance to sorafenib, in vivo [43]. The presented 275 
hypoxia mimicking conditions also induced several metabolism pathways including fructose, 276 
mannose, starch, and sucrose metabolism; as well as glycolysis and gluconeogenesis (Fig. 3). 277 
Nonetheless, without treatment with CoCl2, HepG2 spheroids (group 4 & 5) upregulated genes 278 
were associated with HIF1-α and HIF2-α (Fig. 3A; Table S1). This is consistent with studies 279 
promoting cancer spheroids as candidate solid tumor model, as they recapitulate many aspects 280 
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of in vivo tumors including hypoxia [44]. Hypoxia-mediated pathways in turn promote survival, 281 
angiogenesis, invasion, and metastasis [45]. Hypoxia also plays a role in lipid and steroid 282 
metabolism [46]. Steroids promote tumor immune evasion by suppressing T cell activation and 283 
subsequently effecting immune-therapy outcome [47]. This is consistent with induction of 284 
steroid synthesis and estrogen signaling pathways in group 4 and 5 (physiological hypoxia), but 285 
not group 2 and 3, suggesting that chemically mimicking hypoxia is not sufficient to recapitulate 286 
a more encompassing hypoxic condition (Fig. 3; Table S1). Taken together, these results 287 
demonstrate how adjusting HepG2 cells from 2D to 3D culture introduces hypoxia and its 288 
associated hallmarks, which better represents in vivo cancer conditions. 289 
 290 
Reconstitution of the dynamic bilateral interaction between cancer and stromal cells through 291 
3D co-culture system 292 
Studying the interaction between cancer cells, stromal fibroblasts, and their contribution to 293 
tumorigenesis remains a challenge. We, therefore, created a simplified system to mimic 294 
stroma-tumor interaction. HepG2 cells were either cultured with fibroblasts conditioned media 295 
only (group 3) to mimic one-way interaction or cultured with fibroblasts in a 3D-culture system 296 
(group 5) to mimic a two-way communication. When cultured with fibroblasts, HepG2 297 
upregulated genes were associated with integrin cell surface interactions, in addition to 298 
urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling. Integrin signaling 299 
pathway (ISP) regulates the interaction with the extracellular environment in response to 300 
intracellular cues [48] β1 integrins are overexpressed in many tumors, and blocking their 301 
signaling transduction reduces survival and tumorgenicity of many cancers, in 2D and 3D in vitro 302 
cultures, and in vivo  [49–52]. ISP transduction has been reported to be promoted by other cell 303 
surface proteins, such as urokinase receptor (uPAR) [53]. Suppressing uPAR expression or 304 
disruption uPA/uPAR interaction have been reported to inhibit tumor progression and 305 
metastasis [54]. In addition, canonical pathways associated with the upregulated genes in 306 
group 3 and 5 included IL-6 mediated signaling. This is consistent with Integrin increased 307 
signaling, where enhanced IL-6/STAT3 signaling is promoted by β1-Integrin pathway [55,56]. IL-308 
6 overexpression has been reported in many cancers, including HCC, where it is suggested to 309 
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promote the transition of fibroblasts to CAFs [57]. Indeed, studies have shown CAFs as the main 310 
source of IL-6, promoting survival, migration, invasion, angiogenesis and stemness in colorectal, 311 
gastric, and liver cancer cells [58]. By co-culturing HepG2 cells with fibroblasts, we were able to 312 
recapitulate signaling pathways essential in tumor-stroma crosstalk, creating a more reliable 313 
model to study complex TME interactions. 314 
 315 
Recapitulating signaling pathways in HCC through 3D co-culture system 316 
Insulin/IGF signaling pathway is known to be activated in many cancers including HCC. Studies 317 
have shown its essential role in carcinogenesis and metastasis [59]. The insulin pathway was 318 
generally activated in 3D model (group 5) in comparison to other culturing methods. Many of 319 
the factors involved in insulin pathway – in addition to factors involved in hypoxia, 320 
angiogenesis, and MAPK signaling – were upregulated in our study (Fig. 3 & 4); which was 321 
confirmed on the transcriptome and secretome levels (Fig. 5). HK1 is dramatically upregulated 322 
in group 5 (Fig. 5a). HK1 shows involvement in glycolysis, HIF, and insulin signaling pathways 323 
(Fig. 3A-B), a role that has been reported in various studies; where HK1 contributes to 324 
glycolysis, proliferation, migration, and invasion of HCC [40,60,61]. Similarly, PFKFB3, a direct 325 
target of HIF1, is upregulated in all groups in comparison to group 1 and regulates glucose 326 
metabolism and promotes cancer progression and growth [62]. Overexpression of PFKFB3 is 327 
associated with poor prognosis of HCC, and its inhibition resulted in suppression of HCC growth 328 
in vitro and in vivo [63] and reversed the in vitro sorafenib-resistance of HCC cells [64]. EGLN3, 329 
that mediates crosstalk between hypoxia and insulin signaling pathways [65,66], was 330 
upregulated in HCC hypoxic settings [67,68]. Consistently, EGLN3 was a significant factor driving 331 
hypoxia and insulin pathways in our proposed model (group 5). Culturing HepG2 under 3D co-332 
culture conditions also enhanced the expression of genes promoting angiogenesis, migration, 333 
and invasion such as SERPINE1, ETS1, MMP3, and MMP7. ETS1, MMP3, and MMP7 are only 334 
upregulated in group 5 in comparison to group 1.  ETS1 is involved in upregulating hypoxia-335 
target genes such as MMP3, and MMP7 [69,70]. Downregulation of ETS1 was reported to 336 
inhibit metastasis and invasion of liver cancer cell lines [71]. Similarly, Expression of MMP3 and 337 
MMP7 is correlated with enhanced metastatic phenotype, where their inhibition suppressed 338 
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invasion and migration of HCC cells [18]. SERPINE1 was distinctively upregulated in all groups 339 
compared to group 1, yet, with the highest fold change exhibited in group 5. Increased 340 
expression of PAI-1 (encoded by SERPINE1) is correlated with aggressive cancers and poor 341 
prognosis, where it is also associated with migration, invasion, and angiogenesis in HCC tissue 342 
[72]. Culturing HepG2 under 3D co-culture conditions also downregulated the expression of 343 
genes involved in cell cycle regulation and survival, including E2F2, E2F7, and E2F8. E2F 344 
transcription factors were only differentially expressed in group 5, where they were found to be 345 
downregulated in comparison to group 1, as confirmed by qPCR (Fig. 5a). Downregulation of 346 
E2F2, E2F7, and E2F8 prevents cell cycle arrest and enhances clonogenic survival [73]. Taken 347 
together, these findings indicate that culturing HepG2 in a 3D co-culture system (group 5) 348 
results in enhanced migration, invasion, metastasis, and angiogenesis, and successfully 349 
recapitulating many signaling pathways that are important in HCC in vivo.  350 
 351 
Pathway complementation analysis highlights the involvement of regulatory miRNAs  352 
The cross-talk between cancer cells and other cells in the TME is also partly  mediated through 353 
expression of miRNA and/or release of miRNAs through extracellular vesicles (EVs) [74]. Gene-354 
miRNA interaction network analysis of significant DEGs of group 5 revealed a number of 355 
predicted regulatory miRNAs (Fig. S4, full list in Table S2), many of which are signature of HCC 356 
deregulated miRNAs [39,60]. For instance, miR-335 had the highest number of connections in 357 
group 5 (Fig. S4 a). Serum of HCC patients undergoing TACE was analyzed for circulating miRNAs 358 
level, where miR-335 level was associated with significantly poor prognosis [75]. Thus, EV miR-359 
335 has been suggested as a novel therapeutic strategy as it was shown to be involved in 360 
proliferation and invasion both in vitro and in animal model [76].  Our data suggest an 361 
interesting role of EV-based communication that could be explored in the future using our 362 
novel 3D co-culture HCC model, which resembles a simplified setting of the TME. 363 
 364 
Secretome profiling in our 3D co-culture supports genes expression profiling and 365 
recapitulates in vivo signatures 366 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted November 4, 2021. ; https://doi.org/10.1101/2021.11.04.467266doi: bioRxiv preprint 
 14
Cellular communication between cancer cells and their surrounding is partially driven by 367 
secreted proteins and other soluble factors including cytokines, chemokines, and growth 368 
factors. Using antibody microarrays, we determined the levels of different factors and their 369 
binding proteins that play a role in insulin pathway, angiogenesis, and cytokine signaling (Fig. 5 370 
B-F). Our results show that secretion of insulin/ IGF pathway proteins IGF-2, IGFBP1, and 371 
IGFBP2 is increased by co-culturing HepG2 cells with fibroblasts under 3D co-culture conditions 372 
in comparison to mono-cultures (Fig. 5 B & G). IGF-2 is upregulated in several tumors including 373 
HCC. Its overexpression was notably detected in HCC patient and was shown to induce liver 374 
tumor formation, proliferation and angiogenesis in mice [36]. IGF binding proteins (IGFBPs) are 375 
essential in the IGF signaling axis, where they bind with high affinity to IGF-1 and IGF-2, and 376 
have been reported in HCC patients [59,77].  Granulocyte-, macrophage-, and granulocyte-377 
macrophage- colony-stimulating factors (G-, M-, GM-, respectively) secreted levels have all 378 
increased in 3D co-culture setting in comparison to mono-cultures (Fig. 5 E & G). G-CSF, M-CSF, 379 
and GM-CSF have been shown to be involved in liver regeneration, fibrosis, angiogenesis, and 380 
initiation and progression of liver cancer [78]. Similarly, levels of factors involved in angiogenic 381 
pathway including growth factors, angiopoietins, and matrix metalloproteinases are increased 382 
by co-culturing HepG2 cells with fibroblasts under 3D culture conditions (Fig. 5 C & F-H). 383 
Despite that the 3D model we are proposing herein is restricted to cancer cells and fibroblasts, 384 
present data interestingly shows that our 3D model (group 5 settings) increase the secretion of 385 
several cytokines known to orchestrate the cross-talk between the tumor and its immune TME 386 
(Fig. 5 D & G-), triggering pro-tumor inflammation and immunosuppression [79]. Our pathway 387 
complementation analysis also highlighted two of the enriched genes of group 5 as prognostic 388 
markers, namely IGF1R an EGLN3 (Fig. 5 I-J). Both have been reported as indicators of poor HCC 389 
prognosis [68,80,81]. 390 
 391 
In conclusion, we propose a novel 3D tissue culture model of liver cancer that better mimics in 392 
vivo settings.   Compared to the conventional 2D culture, the proposed model exhibits an 393 
increase in the expression of genes associated with development, progression, and poor 394 
prognosis of HCC. Our results showed that in vivo like conditions cannot be mimicked by simply 395 
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growing cancer cells as spheroids, but by co-culturing them with 3D fibroblast with which they 396 
were able to cross-talk. This was evident by the upregulation of several pathways involved in 397 
HCC, and the dramatic jump in secreted factors and surface receptors by co-cultured cancer 398 
cells, many of which are also involved in tumor-stroma interactions. We have explored the 399 
aspects of HCC our proposed model mimic by combining transcriptome and small scale-400 
secretome analysis, which could be expanded in the future to include proteome analysis.  401 
Compared to the conventional 2D culture, the proposed model exhibits an increase in the 402 
expression of genes associated with development, progression, and poor prognosis of HCC. Our 403 
results correlated with a robust phenotype that better mirrors in vivo HCC, from gene 404 
expression to prognosis markers, and therefore, a more reliable platform for molecular 405 
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FIGURE LEGENDS 647 
 648 
Figure 1. Experimental model and initial validations. a) Schematic depiction of experimental groups. b) 649 
Bright field images of 2D/ 3D HepG2 and fibroblasts cultures fixed and stained with crystal violet and 3D 650 
fibroblasts fixed and stained with neutral red (scale bar = 50 μm). c) Cell viability of HepG2 cells after 651 
treatment with increasing concentrations of CoCl2 for 6 hours (p < 0.01). d) HIF1-α protein expression 652 
was detected in CoCl2 HepG2-treated cells after 6 hours of incubation. Uncropped blots are shown in Fig. 653 
S1. e) Immunofluorescence detection of HIF1-α expression and localization in HepG2 cells incubated 654 
with or without CoCl2 (scale bar = 20 μm).  655 
 656 
Figure 2. Computational analysis of the RNA-Seq of our group cohorts. a) Hierarchical clustering 657 
heatmap of global expression in all groups (in triplicates) was generated with Morpheus using default 658 
settings. B) PCA plot based on global expression in all groups (in triplicates) was generated using 659 
NetworkAnalyst c) PCA plot based on significant DEGs of group 2,3,4,5 in comparison to group 1. d) 660 
Venn diagrams showing the common and unique upregulated genes and downregulated genes of 661 
groups 2, 3, 4, and 5. The interactive diagrams can be accessed online using the InteractiVenn 662 
(http://www.interactivenn.net) and uploading supplementary files 1 & 2c) 663 
 664 
Figure 3. Pathway clustering analysis and heatmap representation of experimental groups. a) Pathway 665 
term clustering based on KEGG pathway maps based on DEGs of experimental groups. All groups are 666 
compared to G1 as the control condition. Node size of pathway terms resemble the number of 667 
associated genes to it. The stronger the node color the more significant a cluster is. b) ORA heatmaps of 668 
enriched genes in denoted pathways based on KEGG from all groups. Heatmaps were generated using 669 
NetworkAnalyst.  670 
 671 
Figure 4. Customized Insulin signaling pathway map of Group 5 DEGs. Insulin signaling pathway 672 
identified as significant through ClueGO/CluePedia pathway term clustering analyzed and customized 673 
through Pathvisio. Red boxes: up regulated genes; green boxes: down regulated genes; gray boxes: 674 
genes not found within the DEGs. Color intensity resembles the deregulated status of the gene from the 675 
LogFC scale (between a 1 to -1 LogFC ). A clear up-regulated trend was identified that resembles the 676 
activation of the pathway and the main genes involved within this mechanism. This customized pathway 677 
map delineates the line of significance from G5 Insulin signaling pathway. These results back-up and 678 
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validate ClueGO/CluePedia analysis. Yellow and blue stars highlight the genes/proteins that were further 679 
validated either through antibody arrays or qPCR respectively. 680 
 681 
Figure 5.  Confirmation studies using genomic, proteomic, and clinical analyses. a) Validation by qPCR. 682 
RNA-Seq based expression was plotted against qPCR-based expression. qPCR data are represented as 683 
means of fold change ± SD. b-f) levels of different secreted factors in 3D mono- and co-cultures analyzed 684 
by antibody arrays. Experimental scheme is outlined in Fig. S2 g) fold change of expression of HepG2 and 685 
Fibroblasts before and after co-culture for markers shown in panels b-f based on RNA-seq data. h) 686 
western blotting of total cell lysates of 2D or 3D HepG2 cultures. Uncropped blots are shown in Fig. S3. i-687 
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